During a February online survey among buy-side advertising decision-makers handling annual ad budgets of at least 250 thousand U.S. dollars in the United States, approximately 40 percent of the participants said they expected the retail and e-commerce industry to cut its ad spending that year due to tariffs. The consumer electronics segment and the media and entertainment sector followed, mentioned by 33 and 28 percent of the respondents, respectively.

During a February online survey among buy-side advertising decision-makers handling annual ad budgets of at least 250 thousand U.S. dollars in the United States, 41 percent of participants anticipated cuts in social media ad spending that year due to tariffs. Gaming and linear TV followed, each mentioned by 24 percent. Approximately 43 percent of respondents cited other traditional media.

BMW CEO Oliver Zipse suggests the EU cut tariffs on U.S. car imports to 2.5% from 10%, aiming to match U.S. rates and ease trade tensions ahead of key EU automotive talks.

This data package includes the underlying data files to replicate the data, tables, and charts presented in Why Trump’s tariff proposals would harm working Americans, PIIE Policy Brief 24-1.

If you use the data, please cite as: Clausing, Kimberly, and Mary E. Lovely. 2024. Why Trump’s tariff proposals would harm working Americans. PIIE Policy Brief 24-1. Washington, DC: Peterson Institute for International Economics.

India's reduction of tariffs on bourbon whisky imports from 150% to 100% is anticipated to boost U.S. brands like Jim Beam and enhance trade relations.

This study extends the analysis of Kovak and Morrow (2022), who study the labor market effects of the FTA by comparing career trajectories for otherwise similar workers whose initial industries subsequently faced different tariff cuts under the FTA. Here, we focus on distributional impacts by examining how the effects of tariff cuts on employment and earnings differed for workers with different initial income levels. Our findings suggest that the effects of the FTA on earnings inequality were small, and the point estimates imply a slight reduction in earnings inequality among workers employed in manufacturing prior to the FTA’s enactment.

Hyundai Steel declares emergency confronting U.S. tariffs and intense competition, exploring cost-cutting strategies including salary cuts and potential U.S. plant establishment to support NA operations.

Goldman Sachs lowers U.S. auto sales forecast by 1 million units due to tariffs, predicting higher vehicle costs and reduced demand.

Canada reduces foreign steel import quotas to support domestic producers amid US-imposed tariffs, with new policies affecting non-trade agreement countries and maintaining leniency for others.

The United States recorded a trade deficit of 71.52 USD Billion in May of 2025. This dataset provides the latest reported value for - United States Balance of Trade - plus previous releases, historical high and low, short-term forecast and long-term prediction, economic calendar, survey consensus and news.

US Tariff Impact on Market

The U.S. tariffs on imported quantum computing hardware and software could impact the post-quantum computing market, especially as quantum processors and related technologies are often sourced globally. These tariffs are estimated to increase costs by 5-10% for U.S.-based companies relying on foreign quantum computing components.

➤➤➤ How your business elevates by our research (Corporate Mail ID Only) @ https://market.us/report/post-quantum-computing-market/free-sample/

This could slow down the rapid adoption of post-quantum technologies, particularly for large enterprises in sectors like BFSI, which are heavily reliant on cutting-edge encryption for security. Companies might absorb the cost, pass it on to customers, or delay projects. This tariff impact will likely increase production costs for U.S. manufacturers, leading to higher costs for software licenses, hardware, and infrastructure necessary to implement quantum solutions.

https://scoop.market.us/wp-content/uploads/2025/04/US-Tariff-Impact-Analysis-in-2025.png" alt="US Tariff Impact Analysis in 2025" class="wp-image-53983">

Economic Impact

The imposition of tariffs on post-quantum computing components could raise operational costs for U.S.-based companies by 5-10%, impacting the pricing structure for post-quantum solutions and slowing down their adoption in high-demand sectors.

Geographical Impact

The tariffs are expected to affect the U.S. market the most, especially in areas relying on international imports for quantum computing infrastructure. International suppliers may experience supply chain delays, and companies in the U.S. may face challenges sourcing affordable and efficient quantum hardware.

Business Impact

Post-quantum computing companies in the U.S. may have to reassess their supply chains or shift to alternate sourcing strategies, which could delay product launches or reduce profit margins. The increased cost burden could potentially deter smaller businesses from adopting quantum solutions, leading to slower market expansion.

Volvo CEO Hakan Samuelsson urges the EU to reduce its 10% car import tariff from the US, emphasizing no need for protection against American automakers.

How Tariffs Are Impacting the Economy

Tariffs imposed on critical defense components and electronic systems essential for Deadhand System manufacturing affect overall costs for defense contractors and governments. U.S. tariffs on imported precision electronics, communication devices, and computing hardware — often sourced from Asia and Europe — increase procurement costs and complicate supply chains.

➤ Discover how our research uncovers business opportunities @ https://market.us/report/deadhand-system-market/free-sample/
(Use corporate mail ID for quicker response)

These tariffs may delay production timelines, increase project budgets, and limit access to cutting-edge technologies. Governments may face challenges in balancing cost control with the need to maintain operational readiness and system modernization. While tariffs aim to protect domestic industries, they can introduce inflationary pressures in defense spending, disrupt multinational supply networks, and slow down deployment of advanced strategic systems.

Indonesia recorded a trade surplus of 4300 USD Million in May of 2025. This dataset provides the latest reported value for - Indonesia Balance of Trade - plus previous releases, historical high and low, short-term forecast and long-term prediction, economic calendar, survey consensus and news.

Introduction

The Global Medical Device Packaging Market is projected to reach USD 85.3 billion by 2033, rising from USD 44.2 billion in 2023. This growth, driven at a compound annual growth rate (CAGR) of 6.8% from 2024 to 2033, is supported by multiple factors. One of the primary drivers is the increasing demand for medical devices. As the global population ages and chronic diseases rise, the demand for medical treatments and tools has grown. This has led to a higher requirement for packaging solutions that ensure the safety and functionality of these devices during storage, transport, and usage.

Sterility and safety are core concerns in medical device packaging. Devices must be kept sterile and undamaged until they are used. Packaging materials are designed to shield products from microbial contamination, physical impact, and environmental changes. The World Health Organization (WHO) stresses that proper packaging is critical to maintaining device integrity and patient safety. Manufacturers are increasingly investing in high-performance packaging systems that meet these sterility standards and prevent device failure.

Regulatory compliance is another significant factor influencing packaging design. The WHO’s Global Model Regulatory Framework for Medical Devices and national health agencies outline strict packaging and labeling standards. These regulations ensure medical devices remain effective and safe throughout their shelf life. As a result, companies must meet global packaging benchmarks to secure product approvals and ensure market access. The demand for compliant packaging materials and systems is expected to continue rising as international regulations become more stringent.

Technological advancements are reshaping the medical device packaging landscape. New materials such as lightweight, durable, and sometimes biodegradable plastics are replacing traditional packaging solutions. In addition, smart packaging technologies are emerging. These can track storage conditions, provide real-time data, and improve user safety. Innovations are also helping reduce material usage and lower overall packaging costs while improving environmental performance.

Sustainability has become a growing concern in the sector. Medical device companies are shifting toward recyclable and biodegradable packaging to minimize environmental harm. This trend is in response to both regulatory pressure and consumer demand for greener products. By reducing waste and using eco-friendly materials, manufacturers can align with global sustainability goals. Together, these factors—rising device demand, regulatory pressure, technology innovations, and environmental concerns—are driving the growth and transformation of the medical device packaging market.

https://market.us/wp-content/uploads/2023/10/Medical-Device-Packaging-Market-By-Size.jpg" alt="Medical Device Packaging Market By Size">

US Tariff Impact on Medical Device Packaging Market

The imposition of U.S. tariffs has raised production costs in the medical device packaging sector. Tariffs on essential materials such as steel, aluminum, and medical-grade plastics have increased input expenses. These materials are critical for ensuring sterile, durable packaging. The U.S. introduced tariffs of up to 125% on some Chinese goods and 10% for others. Such cost burdens often shift along the supply chain, increasing prices for healthcare providers and patients. This has affected the affordability and availability of safe medical packaging solutions across the U.S. healthcare system.

Tariffs have disrupted global supply chains critical to medical device packaging. Approximately 75% of U.S.-marketed medical devices are produced abroad. Of these, around 13.6% are manufactured in China. Key components, such as polymers, electronics, and precision metal parts, are often sourced internationally. Tariff measures have delayed shipments and increased logistics costs. In response, many companies are reassessing sourcing strategies and are considering reshoring production or finding suppliers in tariff-exempt countries to maintain material flow and reduce delays.

Regulatory compliance has become more complex due to changes in suppliers and materials. Manufacturers must requalify products to meet FDA standards if raw materials or processes change. This requalification process is expensive and time-consuming. It delays the availability of compliant products in the market. Meanwhile, higher operational costs have forced many firms to shift budgets away from research and development. This shift reduces investments in innovative packaging technologies and may slow the adoption of sustainable, next-generation packaging formats.

To adapt, firms are employing several strategic measures. These include reshoring production despite higher labor costs, investing in automation to cut manufacturing expenses, and diversifying supplier bases to avoid tariffs. Healthcare providers are also impacted. For example, Providence Health forecasts tariff-related expenses between $10 million and $25 million annually. A survey by Black Book Research predicts healthcare costs could rise by 15% due to tariffs. Despite the challenges, these disruptions are encouraging supply chain innovation and production efficiency upgrades.

U.S. toy makers are cutting costs due to tariffs, impacting accessories and packaging. Learn how this affects holiday shopping.

Thailand recorded a trade surplus of 1060 USD Million in June of 2025. This dataset provides the latest reported value for - Thailand Balance of Trade - plus previous releases, historical high and low, short-term forecast and long-term prediction, economic calendar, survey consensus and news.

The United States' total Exports in 2024 were valued at US$2.06 Trillion, according to the United Nations COMTRADE database on international trade. The United States' main export partners were: Canada, Mexico and China. The top three export commodities were: Mineral fuels, oils, distillation products; Machinery, nuclear reactors, boilers and Electrical, electronic equipment. Total Imports were valued at US$3.36 Trillion. In 2024, The United States had a trade deficit of US$1.29 Trillion.

Introduction

The Global Rivaroxaban Market is projected to grow from USD 16.5 million in 2024 to approximately USD 31.1 million by 2034, expanding at a CAGR of 6.8% during the forecast period. This growth is primarily driven by the drug’s increasing role in preventing thromboembolic disorders, especially among the aging population. Rivaroxaban is a direct oral anticoagulant (DOAC) widely used due to its once-daily dosing and predictable pharmacokinetics. These features make it convenient for long-term use, especially in elderly patients, who represent a major share of the at-risk population for blood clots and stroke.

One of the key drivers for rivaroxaban's adoption is its effectiveness in managing non-valvular atrial fibrillation (AF), a common condition that significantly raises the risk of stroke. Rivaroxaban reduces the risk of stroke and systemic embolism in these patients, offering a viable alternative to traditional anticoagulants. Its oral administration eliminates the need for routine coagulation monitoring, which increases patient compliance. As AF becomes more prevalent globally, rivaroxaban’s relevance in cardiac care continues to rise, supporting market expansion in both developed and emerging economies.

Beyond atrial fibrillation, rivaroxaban is extensively used in the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE). These conditions are major causes of hospitalizations and deaths linked to clotting disorders. Clinical trials have consistently supported rivaroxaban’s efficacy in reducing recurrence rates and improving patient outcomes. Its inclusion in international treatment guidelines has further cemented its role in managing these high-risk conditions. As awareness and diagnosis rates improve, especially in low- and middle-income countries, demand for reliable anticoagulants like rivaroxaban is anticipated to grow.

Another crucial factor enhancing rivaroxaban’s global footprint is its listing on the World Health Organization’s Model List of Essential Medicines. This designation increases accessibility and adoption across public health systems, especially where cost-effective and scalable anticoagulant solutions are in demand. It has encouraged broader distribution through hospital pharmacies, retail chains, and online platforms. In addition, regulatory approvals for pediatric use and expansion into new formulations such as suspension forms support its broader patient reach and therapeutic flexibility.

The growth of the rivaroxaban market is fueled by a mix of clinical efficacy, user-friendly formulation, and international endorsement. Rising incidences of cardiovascular and thromboembolic conditions, combined with the aging global population, contribute to the drug’s increasing adoption. Continued integration into treatment protocols and public health systems is expected to sustain its upward market trajectory through 2034.

https://market.us/wp-content/uploads/2025/01/Rivaroxaban-Market-Size.jpg" alt="Rivaroxaban Market Size">

US Tariff Impact on Rivaroxaban Market

• Tariff-Induced Cost Increases: The imposition of U.S. tariffs on pharmaceutical imports is expected to significantly impact drug pricing. Tariffs on imported finished pharmaceutical products could raise prices for consumers by up to 12.9%, as distributors may pass the added costs downstream. Additionally, tariffs on pharmaceutical ingredients used in domestic manufacturing are projected to increase production costs by 4.1%. These cost pressures may reduce the global competitiveness of U.S.-produced drugs, including rivaroxaban. As a result, both affordability and market performance are likely to be affected adversely.
• Impact on Supply Chain and Quality: Rivaroxaban’s supply chain may face serious strain due to the added cost burden from tariffs. Generic manufacturers, which often operate on low profit margins, may face heightened financial pressure. This could lead to product discontinuations or cost-cutting practices that compromise drug quality. Any disruption in the availability of rivaroxaban could severely impact patients dependent on it for life-threatening conditions like atrial fibrillation and deep vein thrombosis. These risks underscore the vulnerability of pharmaceutical supply chains under tariff pressures.
• Policy Intent vs. Market Reality: Tariffs were implemented with the intent to boost domestic pharmaceutical manufacturing and reduce foreign dependency. However, the actual outcomes may deviate from the intended goals. Higher costs and potential shortages could affect drug availability across the U.S. market. In the case of rivaroxaban, essential for anticoagulation therapy, such impacts may directly affect public health. Policymakers must weigh these adverse effects against the intended economic benefits of trade protectionism.
• Call for Balanced Policy Measures: The rivaroxaban market exemplifies the complex interplay between trade policy and public health. While protecting domestic industry is important, it must not compromise drug affordability and supply. Policymakers should explore alternative solutions such as tax incentives or infrastructure support for local manufacturers. A balanced strategy can help strengthen domestic capabilities while ensuring continued access to essential medications for American patients.

https://media.market.us/wp-content/uploads/2025/05/rivaroxaban-market-tariff-impact-1024x683.png" alt="" class="wp-image-30151">

UBS advises investors to buy silver, forecasting a price rise amid tariff tensions and potential interest rate cuts.